DYN · Dyne Therapeutics, Inc.
$26.10
+0.12 (+0.46%)
At close · Aug 21
Market Cap
$4.87B
Shares
186.75M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$446.21M
-40.6%
FY2025
Diluted EPS
-$3.47
-3%
FY2025
Operating Cash Flow
-$403.21M
-37.9%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| $445.71M | $398.33M | $281.41M | $210.76M | $142.76M | $121.31M | $45.2M | $11.04M | |
| $91.25M | $69.85M | $62.48M | $31.4M | $28.2M | $28.72M | $13.45M | $2.79M | |
| $2.2M | $2.05M | $1.67M | $1.67M | $1.68M | $1.09M | $700K | $271K | |
| $536.96M | $468.18M | $343.89M | $242.16M | $170.96M | $150.03M | $58.65M | $13.83M | |
| -$536.96M | -$468.18M | -$343.89M | -$242.16M | -$170.96M | -$150.03M | -$58.65M | -$13.83M | |
| $17.55M | $21.97M | $26.47M | $6.23M | $2.86M | $734K | -$790K | -$1.03M | |
| — | $0 | $0 | $0 | — | — | — | — | |
| -$73.19M | -$446.21M | -$317.42M | -$235.94M | -$168.1M | -$149.29M | -$59.44M | -$14.86M | |
| -$520.01M | -$445.75M | -$317.41M | -$235.37M | -$168.4M | -$149.53M | -$59.46M | -$14.86M | |
| USD/shares | — | -$3.47 | -$3.37 | -$3.95 | -$3.23 | -$2.93 | — | — |
| USD/shares | — | -$3.47 | -$3.37 | -$3.95 | -$3.23 | -$2.93 | — | — |
| shares | — | — | — | — | — | 50.9M | 14.4M | 2.44M |
| shares | — | — | — | — | — | 50.9M | 14.4M | 2.44M |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 8.57×
EV/EBIT
—
Peer median 29.59×
P/E (TTM)
—
Peer median 19.00×
Peer medians compare against the 204 similar-size Biotechnology companies (of 546 listed).
Key facts
CIK
1818794
CUSIP
26818M108
13F (30d)
231 filings
225 filers
Visit website
Investor relations